Cigna updated its IP0652 policy (effective 2026-03-15) to add neurosarcoidosis guidance under “Other Uses with Supportive Evidence,” citing the 2021 European Respiratory Society recommendation that a TNF inhibitor may be used after trials of glucocorticoids and immunosuppressants. Adalimumab products are eligible under this supportive-evidence pathway but require prior therapy with at least one immunosuppressant (examples: methotrexate, azathioprine, mycophenolate, cyclophosphamide, or infliximab) before approval. Patients already on adalimumab can receive a one-year continuation if they’ve been on therapy ≥3 months, show objective improvement on at least one measure relevant to the organ system, and have symptomatic improvement from baseline. Prescribing should be by or in consultation with an appropriate specialist (e.g., pulmonologist, ophthalmologist, dermatologist) and documentation of objective benefit is required for continued authorization.
March 15, 2026 Revision: Inclusion of Neurosarcoidosis Guidance and Continuation Criteria for Adalimumab
This revision (effective 2026-03-15) for Cigna's IP0652 updates coverage language relevant to use of adalimumab products under the "Other Uses with Supportive Evidence" category, specifically addressing sarcoidosis including neurosarcoidosis. The document explicitly cites the 2021 European Respiratory Society guideline recommendation that a tumor necrosis factor inhibitor (TNFi) may be used for pulmonary and neurosarcoidosis following a trial of glucocorticoids and immunosuppressants. The policy text integrates that guideline context into the Cigna coverage framework.
Additionally, the policy clarifies authorization pathways for patients already receiving an adalimumab product: defined continuity criteria (established on therapy ≥3 months, documented objective benefit by at least one objective measure, and symptom improvement versus baseline) and a one-year approval period when those criteria are met. These elements formalize ongoing-treatment authorization conditions for neurosarcoidosis among other sarcoidosis manifestations.
Evidence Basis: Sarcoidosis and Neurosarcoidosis Placed Under "Other Uses with Supportive Evidence"
The policy places sarcoidosis (including neurosarcoidosis) in the section "Other Uses with Supportive Evidence," noting guideline support rather than primary FDA-approved indications. The supporting citation is the 2021 European Respiratory Society guideline which recommends a TNFi after trials of glucocorticoids and immunosuppressants for pulmonary and neurosarcoidosis. Thus, adalimumab products are recognized by Cigna as supported by evidence/guidelines for neurosarcoidosis but within the "other uses" classification.
This framing indicates that coverage is contingent on meeting the policy's specific clinical and prior-therapy requirements rather than being treated as an automatic on-label indication in this payer document.
Prior-Therapy Requirements and Example Immunosuppressants Listed
The policy specifies prior-therapy requirements before approving adalimumab for these other uses. For initial therapy (criterion A, not fully shown in the excerpt), and for continued therapy (criterion B), the policy enumerates an expectation that patients have tried at least one immunosuppressive medication. Examples listed include methotrexate, leflunomide, azathioprine, mycophenolate mofetil, cyclosporine, chlorambucil (Leukeran), cyclophosphamide, thalidomide (Thalomid), an infliximab product, or chloroquine.
This establishes that Cigna expects prior use of conventional immunosuppressants (or alternative TNFi such as infliximab) before considering adalimumab under the supportive-evidence pathway for sarcoidosis/neurosarcoidosis.
Continuation Criteria for Patients Established on an Adalimumab Product
For patients currently receiving an adalimumab product, the policy authorizes continuation for one year if three explicit criteria are met: (i) the patient has been on therapy for at least 3 months (patients with <3 months or restarting are reviewed as initial therapy); (ii) at least one objective measure demonstrates clinical benefit from baseline (examples include lung function measures such as predicted forced vital capacity or 6-minute walk distance, serum markers like C-reactive protein or NT-proBNP, improvement in rash/skin manifestations, neurologic symptoms, rhythm control, or relevant imaging such as chest radiograph or MRI); and (iii) the patient experienced improvement in at least one symptom (for example decreased cough, fatigue, pain, palpitations, neurologic symptoms, or shortness of breath).
These continuity criteria emphasize documented objective and symptomatic improvement compared with baseline prior to initiating the adalimumab product and delineate the minimum durability on therapy (≥3 months) required for review under the continuation pathway.
Specialist Role and Objective Measures Required for Clinical Benefit Documentation
The policy places prescribing oversight expectations in the supportive-evidence section: adalimumab for these indications should be prescribed by or in consultation with a relevant specialist (explicitly naming pulmonologist, ophthalmologist, or dermatologist) as part of the approval pathway. This appears within the initial-therapy criteria (A) context and frames specialist involvement as part of the documented clinical rationale.
Moreover, objective measures appropriate to the organ system involved are enumerated as examples, reinforcing that assessment for benefit must be tailored (e.g., lung function tests for pulmonary disease, MRI for neurologic involvement) and documented when considering continued coverage for neurosarcoidosis and other sarcoidosis manifestations.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.